Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity (original) (raw)

• Ferrara N . Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527–543.
  Article CAS PubMed Google Scholar
• Klagsbrum M, D'Amore PA . Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259–270.
  Article Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9–22.
  Article CAS PubMed Google Scholar
• Margolin K . Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 2002; 4: 20–28.
  Article PubMed Google Scholar
• Zhu Z, Bohlen P, Witte L . Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002; 2: 135–156.
  Article CAS PubMed Google Scholar
• Zogakis TG, Libutti SK . General aspects of anti-angiogenesis and cancer therapy. Exp Opin Biol Ther 2001; 1: 253–275.
  Article CAS Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245.
  CAS PubMed Google Scholar
• Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J . Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815–821.
  CAS PubMed PubMed Central Google Scholar
• Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508.
  Article CAS PubMed Google Scholar
• Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398–1401.
  Article CAS PubMed PubMed Central Google Scholar
• Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637–2644.
  CAS PubMed Google Scholar
• Hussong JW, Rodgers GM, Shami PJ . Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313.
  CAS PubMed Google Scholar
• Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875.
  CAS PubMed Google Scholar
• Bellamy WT, Richter L, Frutiger Y, Grogan TM . Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728–733.
  CAS PubMed Google Scholar
• Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721.
  CAS PubMed Google Scholar
• Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 768–770.
  CAS PubMed Google Scholar
• Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001; 7: 795–799.
  CAS PubMed Google Scholar
• Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemia cell growth and migration. J Clin Invest 2000; 106: 511–521.
  Article CAS PubMed PubMed Central Google Scholar
• Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS . Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904–1913.
  Article CAS PubMed Google Scholar
• Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434.
  Article CAS PubMed Google Scholar
• Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 2000; 60: 2527–2534.
  CAS PubMed Google Scholar
• Fiedler W, Staib P, Kuse R, Duhrsen U, Flasshove M, Cavalli F et al. Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J Supl 2001; 3: S1 29–S133.
  Google Scholar
• Bellamy WT . Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001; 28: 551–559.
  Article CAS PubMed Google Scholar
• List A . Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. The Oncologist 2001; 6: 24–31.
  Article CAS PubMed Google Scholar
• Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857–10862.
  Article CAS PubMed PubMed Central Google Scholar
• Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241–243.
  Article CAS PubMed Google Scholar
• Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM . The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001; 97: 1413–1421.
  Article CAS PubMed Google Scholar
• Zhu Z, Hicklin DJ, Bohlen B, Waskal H, Witte L . Clinical development of antibody-based receptor tyrosine kinase inhibitors for cancer therapy. In: Recent Research Developments in Cancer, Vol. 3. Trivandrum: Transworld Research Network, 2001; pp 369–384.
  Google Scholar
• Glennie MJ, Johnson PWM . Clinical trials of antibody therapy. Immunol Today 2000; 21: 403–410.
  Article CAS PubMed Google Scholar
• Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998; 58: 3209–3214.
  CAS PubMed Google Scholar
• Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T et al. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett 1999; 136: 203–213.
  Article CAS PubMed Google Scholar
• Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z . Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97: 393–399.
  Article CAS PubMed Google Scholar
• Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L et al. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J Biol Chem 2000; 275: 14321–14330.
  Article CAS PubMed Google Scholar
• De Haard HJ, va Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx de P et al. A large non-immunized human Fab fragment phage library that permit rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274: 18218–18230.
  Article CAS PubMed Google Scholar
• Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B et al. Placenta growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone marrow microenvironment. Nat Med 2002; 8: 841–849.
  Article CAS PubMed PubMed Central Google Scholar
• Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-flt1. Nat Med 2002; 8: 831–840.
  Article CAS PubMed Google Scholar
• Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M . Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61: 1207–1213.
  CAS PubMed Google Scholar
• Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17: 155–161.
  Article CAS PubMed Google Scholar
• Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K et al. Antivascular endothelial growth factor receptor (Fetal Liver Kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209–5218.
  CAS PubMed Google Scholar
• Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–844.
  Article CAS PubMed Google Scholar
• Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77: 933–936.
  Article CAS PubMed Google Scholar
• Fong TA, Shawver LK, Sun L, Tang C, App H, Powell JT et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99–106.
  CAS PubMed Google Scholar
• Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178–2189.
  CAS PubMed Google Scholar
• Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000; 6: 2094–2103.
  CAS PubMed Google Scholar
• Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates hemotopoietic stem cell survial by an internal autocrine loop mechanism. Nature 2002; 417: 954–958.
  Article CAS PubMed Google Scholar
• Ziegler BL, Valtieri M, Porada GA, De Maria R, Muller R, Masella B et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 1999; 285: 1553–1558.
  Article CAS PubMed Google Scholar
• Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Writte L et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, _fms_-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 2001; 61: 7002–7008.
  CAS PubMed Google Scholar
• Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000; 19: 2138–2146.
  Article CAS PubMed Google Scholar
• Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR . Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001; 159: 651–659.
  Article CAS PubMed PubMed Central Google Scholar
• Boocock CA, Charnock-Jones DS, Sharkey AM, Mclaren J, Barker PJ, Wright KA et al. Expression of vascular endothelial growth factor and its receptors flt and kdr in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–516.
  Article CAS PubMed Google Scholar
• Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M . Concomitant overexpression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27–34.
  Article CAS PubMed Google Scholar
• Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H . Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12: 129–135.
  CAS PubMed Google Scholar
• Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000; 115: 1000–1007.
  Article CAS PubMed Google Scholar
• Little M, Kipriyanov SM, Gall FL, Moldenhauer G . Of mice and men: hybridoma and recombinant antibodies. Immunol Today 2000; 21: 364–370.
  Article CAS PubMed Google Scholar
• Hoogenboom HR, Chames P . Natural and designer binding sites made by phage display technology. Immunol Today 2000; 21: 371–378.
  Article CAS PubMed Google Scholar